Alzheimer’s Disease – a new preclinical model
As announced a few weeks ago, we tested the effects of donepezil (DPZ) in our Alzheimer’s disease model, induced by the administration of beta-amyloid oligomers 1-42.
We have shown that memory disorders induced by A-Beta oligomers could be significantly reduced by this symptomatic treatment of Alzheimer’s disease. This strengthens the pharmacological validity of our model. In addition, we have once again shown the reproducibility of our model.
We have shown that the deleterious effects on memory induced by the administration of A-beta 1-42 are significantly reduced in the object recognition test. Animals in the ABO group show poorer memory performance than animals in the Vehicle group, yet the memory performance of animals in the ABO-DPZ group is comparable to that of the Vehicle group (Fig 1a). The results obtained in the Morris water maze test are consistent with these findings; the animals in the Vehicle and ABO-DPZ groups improved their access time to the platform, showing a preference for the area close to the platform during the Probe Trial, whereas the animals in the ABO group showed poorer memory performance than the Vehicle group (Fig 1b).
Figure 1: Graphic representation of memory performances in a)Novel Object Recognition test and b) Morris Watermaze
These replicated results show that the administration of DZP can mask the effects of the ICV injection of ABO, restoring the animals’ ability to learn in both a short-term memory (NOR) testand a long-term spatial memory (MWM) test
We will soon be sharing our biological analysis results with you! To keep up with the latest news on this, please follow our linkedin ETAP-Lab page.
Should you require any further information, please feel free to contact us .
This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the operational programme “FEDER-FSE Lorraine et Massif des Vosges 2014-2020”